Larimar Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 9.43 million compared to USD 9.13 million a year ago. Basic loss per share from continuing operations was USD 0.21 compared to USD 0.5 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.38 USD | +4.24% | -6.46% | +62.20% |
May. 21 | Sector Update: Health Care Stocks Steady Premarket Tuesday | MT |
May. 21 | Investors Tread Cautiously as Nvidia Earnings Loom, Driving Muted Premarket Action for US Equity Futures | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.20% | 471M | |
+9.83% | 115B | |
+10.80% | 105B | |
-10.84% | 22.71B | |
-1.69% | 21.83B | |
-10.23% | 18.18B | |
-41.92% | 16.52B | |
-15.11% | 16.01B | |
+6.62% | 14.14B | |
+17.53% | 10.71B |
- Stock Market
- Equities
- LRMR Stock
- News Larimar Therapeutics, Inc.
- Larimar Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022